SQZ Biotechnologies (SQZ)

SQZ Biotechnologies is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Using its proprietary technology, SQZ Biotechnologies offers the unique ability to deliver multiple materials into many patient cell types to engineer what SQZ Biotechnologies believes can be an unprecedented range of potential therapeutics for a variety of diseases. SQZ Biotechnologies has the potential to create well-tolerated cell therapies that can provide therapeutic benefit for patients and to improve the patient experience over existing cell therapy approaches. With accelerated production timelines under 24 hours and the opportunity to eliminate preconditioning and lengthy hospital stays, its goal is to use the SQZ approach to establish a new paradigm for cell therapies. The Company's first therapeutic applications aim to leverage the potential to generate target-specific immune responses, both in activation for the treatment of solid tumors and immune tolerance for the treatment of unwanted immune reactions and autoimmune diseases.

Company profile

Fiscal year end
SQZ Biotechnologies Security Corporation • SQZ Biotech HK Limited ...
IRS number

SQZ stock data

Investment data

Data from SEC filings
Securities sold
Number of investors


4 Aug 22
1 Oct 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 107.87M 107.87M 107.87M 107.87M 107.87M 107.87M
Cash burn (monthly) 5.78M 6.63M 7.5M 6.49M 6.83M 6.9M
Cash used (since last report) 17.76M 20.34M 23.03M 19.92M 20.96M 21.19M
Cash remaining 90.11M 87.52M 84.83M 87.95M 86.91M 86.67M
Runway (months of cash) 15.6 13.2 11.3 13.6 12.7 12.6

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
15 Aug 22 Richard Capasso Common Stock Sell Dispose S No No 3.3262 1,183 3.93K 0
11 Jul 22 Micah Zajic Stock Option Common Stock Grant Acquire A No No 3.23 10,000 32.3K 10,000
30 Jun 22 Richard Capasso Common Stock Grant Acquire A No No 2.703 1,183 3.2K 1,183
30 Jun 22 Lawrence J Knopf Common Stock Grant Acquire A No No 2.703 1,484 4.01K 1,938
30 Jun 22 Armon Sharei Common Stock Grant Acquire A No No 2.703 2,436 6.58K 287,884
57.3% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 55 54 +1.9%
Opened positions 18 9 +100.0%
Closed positions 17 6 +183.3%
Increased positions 11 11
Reduced positions 15 19 -21.1%
13F shares Current Prev Q Change
Total value 130.95M 159.89M -18.1%
Total shares 20.6M 21.6M -4.6%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Temasek 2.76M $8.77M 0.0%
Management Co. VII, L.L.C. Polaris 2.73M $24.36M 0.0%
AIG American International 2.52M $8.01M -0.4%
683 Capital Management 2.16M $6.86M +2.8%
Artal 1.61M $5.11M 0.0%
Invus Public Equities 1.61M $46.55M 0.0%
NanoDimension II Management 1.45M $12.91M 0.0%
NanoDimension 1.45M $4.6M 0.0%
Maverick Capital 1.07M $3.4M +1.1%
Vanguard 941.4K $2.99M -7.8%
Largest transactions Shares Bought/sold Change
BLK Blackrock 286.64K -1.09M -79.3%
Laurion Capital Management 431.4K +431.4K NEW
STT State Street 56.14K -296.76K -84.1%
SF Stifel Financial 465.03K +290.06K +165.8%
Geode Capital Management 121.6K -190.63K -61.1%
NTRS Northern Trust 31.02K -150.52K -82.9%
Ergoteles 104.32K +104.32K NEW
Millennium Management 92.29K +92.29K NEW
RBF Capital 80K +80K NEW
Vanguard 941.4K -79.4K -7.8%

Content analysis

H.S. junior Avg
New words: agency, agent, agreed, ATM, budget, LLC, macroeconomic, National, NIH, recoverability, setup, unbilled
Removed: China, invested, lower, papilloma, surfaced, technical, transferring, Wuhan